Cara Therapeutics Inc (CARA)
0.70
+0.03
(+4.23%)
USD |
NASDAQ |
Apr 25, 16:00
0.7063
+0.01
(+0.90%)
After-Hours: 20:00
Cara Therapeutics Cash and Short Term Investments (Quarterly): 100.76M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 100.76M |
| September 30, 2023 | 78.54M |
| June 30, 2023 | 94.69M |
| March 31, 2023 | 114.28M |
| December 31, 2022 | 145.40M |
| September 30, 2022 | 155.61M |
| June 30, 2022 | 157.51M |
| March 31, 2022 | 141.11M |
| December 31, 2021 | 167.04M |
| September 30, 2021 | 144.19M |
| June 30, 2021 | 155.18M |
| March 31, 2021 | 171.58M |
| December 31, 2020 | 180.92M |
| September 30, 2020 | 120.87M |
| June 30, 2020 | 130.18M |
| March 31, 2020 | 120.20M |
| December 31, 2019 | 155.01M |
| September 30, 2019 | 193.09M |
| June 30, 2019 | 115.31M |
| March 31, 2019 | 134.45M |
| December 31, 2018 | 161.38M |
| September 30, 2018 | 206.08M |
| Date | Value |
|---|---|
| June 30, 2018 | 131.96M |
| March 31, 2018 | 74.52M |
| December 31, 2017 | 92.57M |
| September 30, 2017 | 102.98M |
| June 30, 2017 | 112.44M |
| March 31, 2017 | 36.81M |
| December 31, 2016 | 58.28M |
| September 30, 2016 | 71.42M |
| June 30, 2016 | 84.76M |
| March 31, 2016 | 96.24M |
| December 31, 2015 | 106.74M |
| September 30, 2015 | 111.12M |
| June 30, 2015 | 43.19M |
| March 31, 2015 | 47.42M |
| December 31, 2014 | 52.66M |
| September 30, 2014 | 58.39M |
| June 30, 2014 | 62.81M |
| March 31, 2014 | 67.04M |
| December 31, 2013 | 12.36M |
| September 30, 2013 | 17.73M |
| December 31, 2012 | 1.117M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
78.54M
Minimum
Sep 2023
193.09M
Maximum
Sep 2019
139.02M
Average
144.19M
Median
Sep 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Nektar Therapeutics | 303.62M |
| Stereotaxis Inc | 19.82M |
| Cerus Corp | 65.85M |
| Avid Bioservices Inc | 30.71M |
| Rigel Pharmaceuticals Inc | 56.93M |